• Miguel Cervero, Rafael Torres, Juan José Jusdado, Susana Pastor, and Jose Luis Agud.
• Departamento de Medicina Interna, Hospital Universitario Severo Ochoa , Leganés, Madrid, España. Electronic address: mcerveroj@gmail.com.
• Med Clin (Barc). 2016 Apr 15; 146 (8): 339-45.

Background And ObjectiveTo determine the prevalence and types of clinically significant drug-drug interactions (CSDI) in the drug regimens of HIV-infected patients receiving antiretroviral treatment.Material And MethodsDesignretrospective review of database. Centre: Hospital Universitario Severo Ochoa, Infectious Unit.Participantsone hundred and forty-two participants followed by one of the authors were selected from January 1985 to December 2014.Data Collectionfrom their outpatient medical records we reviewed information from the last available visit of the participants, in relation to HIV infection, comorbidities, demographics and the drugs that they were receiving; both antiretroviral drugs and drugs not related to HIV infection. We defined CSDI from the information sheet and/or database on antiretroviral drug interactions of the University of Liverpool (http://www.hiv-druginteractions.org) and we developed a diagnostic tool to predict the possibility of CSDI. By multivariate logistic regression analysis and by estimating the diagnostic performance curve obtained, we identified a quick tool to predict the existence of drug interactions.ResultsOf 142 patients, 39 (29.11%) had some type of CSDI and in 11.2% 2 or more interactions were detected. In only one patient the combination of drugs was contraindicated (this patient was receiving darunavir/r and quetiapine). In multivariate analyses, predictors of CSDI were regimen type (PI or NNRTI) and the use of 3 or more non-antiretroviral drugs (AUC 0.886, 95% CI 0.828 to 0.944; P=.0001). The risk was 18.55 times in those receiving NNRTI and 27,95 times in those receiving IP compared to those taking raltegravir.ConclusionsDrug interactions, including those defined as clinically significant, are common in HIV-infected patients treated with antiretroviral drugs, and the risk is greater in IP-based regimens. Raltegravir-based prescribing, especially in patients who receive at least 3 non-HIV drugs could avoid interactions.Copyright © 2016 Elsevier España, S.L.U. All rights reserved.

36 keywords...

hide…